Aspira Women's Health Financial Statements (AWH)
|
|
|
|
Report date
|
|
|
31.03.2022 |
30.03.2023 |
01.04.2024 |
27.03.2025 |
01.04.2026 |
|
15.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
6.81 |
8.18 |
9.15 |
9.18 |
9.22 |
|
8.90 |
|
Operating Income, bln rub |
|
|
-32.6 |
-31.1 |
-18.9 |
-16.3 |
-7.91 |
|
-6.88 |
|
EBITDA, bln rub |
? |
|
-32.3 |
-30.9 |
-16.5 |
-16.2 |
-7.91 |
|
-8.29 |
|
Net profit, bln rub |
? |
|
-31.7 |
-29.9 |
-16.7 |
-13.1 |
-12.8 |
|
-10.3 |
|
|
OCF, bln rub |
? |
|
-27.4 |
-31.1 |
-15.9 |
-12.1 |
-7.03 |
|
-4.29 |
|
CAPEX, bln rub |
? |
|
0.184 |
0.232 |
0.024 |
0.037 |
0.016 |
|
0.016 |
|
FCF, bln rub |
? |
|
-27.6 |
-31.3 |
-15.9 |
-12.2 |
-7.05 |
|
-4.30 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
|
|
|
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
35.7 |
37.1 |
24.1 |
21.8 |
13.8 |
|
12.3 |
|
Cost of production, bln rub |
|
|
3.75 |
3.87 |
3.89 |
3.70 |
3.30 |
|
3.48 |
|
R&D, bln rub |
|
|
5.31 |
5.95 |
4.04 |
3.27 |
2.88 |
|
3.13 |
|
Interest expenses, bln rub |
|
|
0.048 |
0.000 |
0.000 |
0.033 |
0.041 |
|
0.258 |
|
|
Assets, bln rub |
|
|
41.1 |
17.4 |
6.26 |
5.49 |
5.46 |
|
5.09 |
|
Net Assets, bln rub |
? |
|
30.2 |
6.98 |
-2.37 |
-2.56 |
-6.93 |
|
-6.21 |
|
Debt, bln rub |
|
|
4.11 |
3.83 |
2.85 |
3.38 |
2.49 |
|
2.39 |
|
Cash, bln rub |
|
|
37.2 |
13.3 |
2.60 |
1.77 |
1.76 |
|
1.34 |
|
Net debt, bln rub |
|
|
-33.1 |
-9.48 |
0.26 |
1.61 |
0.73 |
|
1.04 |
|
|
Ordinary share price, rub |
|
|
26.6 |
4.95 |
4.08 |
0.705 |
|
|
|
|
Number of ordinary shares, mln |
|
|
7.41 |
8.06 |
9.23 |
14.1 |
34.1 |
|
43.5 |
|
|
Market cap, bln rub |
|
|
197 |
40 |
38 |
10 |
0 |
|
0 |
|
EV, bln rub |
? |
|
164 |
30 |
38 |
12 |
1 |
|
1 |
|
Book value, bln rub |
|
|
30 |
7 |
-2 |
-3 |
-7 |
|
-6 |
|
|
EPS, rub |
? |
|
-4.28 |
-3.71 |
-1.81 |
-0.93 |
-0.37 |
|
-0.24 |
|
FCF/share, rub |
|
|
-3.72 |
-3.88 |
-1.72 |
-0.86 |
-0.21 |
|
-0.10 |
|
BV/share, rub |
|
|
4.07 |
0.87 |
-0.26 |
-0.18 |
-0.21 |
|
-0.15 |
|
|
EBITDA margin, % |
? |
|
-474.1% |
-377.2% |
-180.2% |
-176.3% |
-85.9% |
|
-93.1% |
|
Net margin, % |
? |
|
-465.5% |
-365.2% |
-182.3% |
-142.6% |
-138.7% |
|
-115.1% |
|
FCF yield, % |
? |
|
-14.0% |
-78.4% |
-42.3% |
-121.9% |
|
|
|
|
ROE, % |
? |
|
-105.1% |
-428.2% |
705.7% |
510.9% |
184.4% |
|
165.2% |
|
ROA, % |
? |
|
-77.2% |
-172.0% |
-266.5% |
-238.5% |
-234.2% |
|
-201.5% |
|
|
P/E |
? |
|
-6.21 |
-1.34 |
-2.26 |
-0.76 |
0.00 |
|
0.00 |
|
P/FCF |
|
|
-7.14 |
-1.27 |
-2.37 |
-0.82 |
0.00 |
|
0.00 |
|
P/S |
? |
|
28.9 |
4.88 |
4.12 |
1.09 |
0.00 |
|
0.00 |
|
P/BV |
? |
|
6.52 |
5.72 |
-15.9 |
-3.89 |
0.00 |
|
0.00 |
|
EV/EBITDA |
? |
|
-5.07 |
-0.99 |
-2.30 |
-0.71 |
-0.09 |
|
-0.13 |
|
Debt/EBITDA |
|
|
1.02 |
0.31 |
-0.02 |
-0.10 |
-0.09 |
|
-0.13 |
|
|
R&D/CAPEX, % |
|
|
2 888% |
2 566% |
16 813% |
8 827% |
17 988% |
|
19 569% |
|
|
CAPEX/Revenue, % |
|
|
2.70% |
2.83% |
0.26% |
0.40% |
0.17% |
|
0.18% |
|
| Aspira Women's Health shareholders |
